FDA Approval Granted to Begin Clinical Trial
KoDiscovery, LLC and NewG Lab Pharma, LLC have submitted the comprehensive IND (Investigational New Drug) application to the FDA for approval to begin a unique, combined Phase I/ II-A clinical trial for primary liver cancer.
The IND has been extensively reviewed by the FDA and has been accepted, which now grants FDA approval to begin the first clinical trial with Dr. Ko’s KAT formulation!
Please visit the KoDiscovery website for more information.
FDA Approval Granted to Begin Clinical Trial